U.S. stocks moving strangely | Septerna (SEPN.US) surges 67% before market open, will collaborate with Novo Nordisk to develop oral weight loss medication.

According to the 36Kr Finance APP, Novo Nordisk (NVO.US) has agreed to jointly develop and commercialize an oral small molecule drug for the treatment of obesity and other cardiovascular metabolic diseases with Septerna (SEPN.US). The deal is valued at up to $2.2 billion. In response to this news, Septerna surged 67% in pre-market trading.